Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Harvard Business School
Mallinckrodt
AstraZeneca
Express Scripts

Last Updated: May 24, 2022

Duvelisib - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

What are the generic drug sources for duvelisib and what is the scope of freedom to operate?

Duvelisib is the generic ingredient in one branded drug marketed by Secura and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Duvelisib has one hundred and forty-seven patent family members in thirty-four countries.

Summary for duvelisib
International Patents:147
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 66
Clinical Trials: 40
Patent Applications: 1,911
Drug Prices: Drug price trends for duvelisib
What excipients (inactive ingredients) are in duvelisib?duvelisib excipients list
DailyMed Link:duvelisib at DailyMed
Drug Prices for duvelisib

See drug prices for duvelisib

Recent Clinical Trials for duvelisib

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Emory UniversityEarly Phase 1
NovartisEarly Phase 1
Secura Bio, Inc.Early Phase 1

See all duvelisib clinical trials

US Patents and Regulatory Information for duvelisib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Secura COPIKTRA duvelisib CAPSULE;ORAL 211155-001 Sep 24, 2018 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Secura COPIKTRA duvelisib CAPSULE;ORAL 211155-001 Sep 24, 2018 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Secura COPIKTRA duvelisib CAPSULE;ORAL 211155-002 Sep 24, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Secura COPIKTRA duvelisib CAPSULE;ORAL 211155-002 Sep 24, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Secura COPIKTRA duvelisib CAPSULE;ORAL 211155-002 Sep 24, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Secura COPIKTRA duvelisib CAPSULE;ORAL 211155-001 Sep 24, 2018 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for duvelisib

Country Patent Number Title Estimated Expiration
New Zealand 613219 Heterocyclic containing entities, compositions and methods See Plans and Pricing
New Zealand 717410 Heterocyclic containing entities, compositions and methods See Plans and Pricing
Canada 2824197 PROCEDES DE PREPARATION D'ISOQUINOLINONES ET DE FORMES SOLIDES D'ISOQUINOLINONES (PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES) See Plans and Pricing
Taiwan 201906841 Processes for preparing isoquinolinones and solid forms of isoquinolinones See Plans and Pricing
Singapore 191897 PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES See Plans and Pricing
South Korea 20140020249 PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for duvelisib

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2456444 132021000000173 Italy See Plans and Pricing PRODUCT NAME: DUVELISIB(COPIKTRA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/21/1542, 20210521
2456444 2021C/546 Belgium See Plans and Pricing PRODUCT NAME: DUVELISIB; AUTHORISATION NUMBER AND DATE: EU/1/21/1542/001-002 20210521
2456444 46/2021 Austria See Plans and Pricing PRODUCT NAME: DUVELISIB; REGISTRATION NO/DATE: EU/1/21/1542 (MITTEILUNG) 20210521
2456444 CA 2021 00045 Denmark See Plans and Pricing PRODUCT NAME: DUVELISIB; REG. NO/DATE: EU/1/21/1542 20210521
2456444 LUC00237 Luxembourg See Plans and Pricing PRODUCT NAME: DUVELISIB; AUTHORISATION NUMBER AND DATE: EU1/21/1542 20210521
2456444 PA2021526 Lithuania See Plans and Pricing PRODUCT NAME: DUVELISIBAS; REGISTRATION NO/DATE: EU/1/21/1542 20210519
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Baxter
Moodys
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.